BEERSE, April 25 2014 – Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved VOKANAMET® (a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet) in the European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control.[1] Canagliflozin as a single agent was approved as INVOKANA® in the European Union in November 2013.[2]
VOKANAMET® (canagliflozin and immediate release metformin hydrochloride fixed dose combination) approved in the European Union for treatment of adults with type 2 diabetes [1] | Johnson & Johnson
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.